Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carfilzomib + prednisone
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Carfilzomib + prednisone is a **combination chemotherapy regimen** consisting of carfilzomib, a proteasome inhibitor, and prednisone, a synthetic glucocorticoid corticosteroid. **Carfilzomib selectively inhibits the 20S proteasome**, leading to disrupted protein homeostasis, accumulation of unwanted proteins, and apoptosis of cancer cells, particularly in multiple myeloma[3][1]. **Prednisone exerts immunosuppressive and anti-inflammatory effects**, and is commonly used in oncology regimens to enhance apoptosis or mitigate adverse effects. This combination is mainly investigated for **multiple myeloma**, with clinical studies emphasizing its use in elderly or transplant-ineligible patients[1][6]. Carfilzomib is developed by Amgen and marketed under the brand name Kyprolis, primarily administered intravenously, while prednisone is taken orally.
- Other names
- carfilzomib + prednisone
02
Targets
PSMB7 (Proteasome subunit beta type-7)PSMB5 (Proteasome subunit beta Type-5)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on carfilzomib + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carfilzomib + prednisone.